ZNF703 is a gene which has been linked with the development of breast cancers.[5][6][7] ZNF703 is contained within the NET/N1z family responsible for regulation of transcription essential for developmental growth especially in the hindbrain.[8] Normal functions performed by ZNF703 include adhesion, movement and proliferation of cells.[8] ZNF703 directly accumulates histone deacetylases at gene promoter regions but does not bind to functional DNA.[9]
| zinc finger protein 703 | |
|---|---|
| Identifiers | |
| Symbol | ZNF703 |
| NCBI gene | 80139 |
| HGNC | 25883 |
| RefSeq | NM_025069 |
| Other data | |
| Locus | Chr. 8 p12 |
Following research by scientists at Cancer Research UK, it was the first oncogene discovery in the past six years.[6]
ZNF703 is a part of 8p12 telomeric amplicon that is associated with Luminal B breast cancer. Recently, ZNF703 is identified as the driver of 8p12 locus amplification.[10]
Patients diagnosed with luminal B cancer caused by ZNF703 typically have lower recovery and survival rates than other cancer types.[11]
Drug resistance of ZNF703 has been displayed when patients are treated using anti-cancer drug Tamoxifen.[12]
Discovery edit
Researchers discovered the carcinogenic nature of ZNF703 in 2011 while conducting research on the classification and resistance of various oncogenes.[8] Researchers attempted to discern factors associated with various cancer types through observation of the oncogenic mechanism on a molecular scale.[8] The luminal B cancer pathway exhibited an amplification of 5 different genomic areas including the chromosome region 8p12.[8] Amplification of region 8p12 occurred through transcriptional regulation of ZNF703.[8]
Location edit
ZNF703 is located on human chromosome 8 at the short arm region commonly named chromosome region 8p12.[5] Tumors generated by ZNF703 have shown loss in size beginning at the telomere and ending at 8p12 while the 8p12-11 region has increased size.[13] A fluctuation between increase and decrease is present along the 8p12-8p21 boundary region of the chromosome.[13] A pattern has been found that involves three similar regions of disrupted growth and four regions of enhanced growth starting from the telomere and ending at the centromere.[13]
Role in cancer edit
The ZNF703 gene generally plays an active role in luminal B tumor cells contained in mammary ducts.[5] Typically, ZNF703 expression is greater when the tumors are estrogen receptor positive as opposed to estrogen receptor negative.[5] ZNF703 is co-expressed in a nuclear complex containing genes DCAF7, NCRO2 and PHB2.[5] ZNF703 generates a nuclear protein responsible for oestrogen receptor associated protein repression.[5] Gene expression of stem cells are triggered when the ZNF703 gene becomes overexpressed in the complex.[5] As a result, both regular cells and cancer stem cell abundance increases rapidly.[5] ZNF703 overexpression also causes primary and secondary tumorsphere development alongside amplified production of CD49F- positive cells associated with colon cancer.[5]
ZNF703 also experiences target regulation of cancer cells through the transcription of RNA SPRY4-It1.[14] RNA SPRY4-IT1 is a non-coding gene responsible for preventing apoptosis and generating large tumors.[14]
Researchers recently established a link between the trigger gene ZNF703 and Akt/mTOR pathway activation involved in the cellular cycle resulting in lung tumor formation.[15]
Prognosis edit
The lifespan of individuals with colorectal cancer and luminal cancer have different prognosis depending on the amount of expression of the ZNF703 gene.[11] Low amounts of transcription of ZNF703 usually leads to a healthier prognosis than individuals experiencing higher levels of transcription of the oncogene.[11] ZNF703 is a target for therapeutic medicines since survival rates increase as transcription rates decrease.[11]
Resistance to drugs edit
The drug Tamoxifen is a commonly administered drug used to treat luminal cancers in patients.[12] Half of patients treated with Tamoxifen are resistant to the drug.[12] Overexpression of ZNF703 has been linked to Tamoxifen resistance.[12] As transcription of the ZNF703 gene reaches substantial levels, instead of blocking cell proliferation, Tamoxifen is found to increase cancer cell division.[12] Tamoxifen can only be given at low dosages and patients are monitored daily in order to avoid tumor growth.[12]
References edit
- ^ a b c GRCh38: Ensembl release 89: ENSG00000183779 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000085795 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ a b c d e f g h i Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, et al. (March 2011). "ZNF703 gene amplification at 8p12 specifies luminal B breast cancer". EMBO Molecular Medicine. 3 (3): 153–166. doi:10.1002/emmm.201100121. PMC 3395112. PMID 21328542.
- ^ a b "BBC News - Key breast cancer 'driver' gene found". 2011-02-18. Retrieved 2011-02-18.
- ^ Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG (April 2009). "Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis". Oncogene. 28 (17): 1892–1903. doi:10.1038/onc.2009.34. PMC 2722962. PMID 19330026.
- ^ a b c d e f Yang G, Ma F, Zhong M, Fang L, Peng Y, Xin X, et al. (April 2014). "ZNF703 acts as an oncogene that promotes progression in gastric cancer". Oncology Reports. 31 (4): 1877–1882. doi:10.3892/or.2014.2997. PMID 24481460.
- ^ Nakamura M, Choe SK, Runko AP, Gardner PD, Sagerström CG (November 2008). "Nlz1/Znf703 acts as a repressor of transcription". BMC Developmental Biology. 8: 108. doi:10.1186/1471-213x-8-108. PMC 2588584. PMID 19014486.
- ^ Holland DG, Burleigh A, Git A, Goldgraben MA, Perez-Mancera PA, Chin SF, et al. (March 2011). "ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium". EMBO Molecular Medicine. 3 (3): 167–180. doi:10.1002/emmm.201100122. PMC 3395113. PMID 21337521.
- ^ a b c d Ma F, Bi L, Yang G, Zhang M, Liu C, Zhao Y, et al. (September 2014). "ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer". Oncology Reports. 32 (3): 1071–1077. doi:10.3892/or.2014.3313. PMID 25017610.
- ^ a b c d e f Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M, Shen K (2013-08-26). "Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling". PLOS ONE. 8 (8): e72053. Bibcode:2013PLoSO...872053Z. doi:10.1371/journal.pone.0072053. PMC 3753350. PMID 23991038.
- ^ a b c Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, et al. (December 2005). "Comprehensive profiling of 8p11-12 amplification in breast cancer". Molecular Cancer Research. 3 (12): 655–667. doi:10.1158/1541-7786.mcr-05-0128. PMID 16380503.
- ^ a b Shi Y, Li J, Liu Y, Ding J, Fan Y, Tian Y, et al. (February 2015). "The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression". Molecular Cancer. 14: 51. doi:10.1186/s12943-015-0318-0. PMC 4350857. PMID 25742952.
- ^ Baykara O, Dalay N, Kaynak K, Buyru N (October 2016). "ZNF703 Overexpression may act as an oncogene in non-small cell lung cancer". Cancer Medicine. 5 (10): 2873–2878. doi:10.1002/cam4.847. PMC 5083741. PMID 27650486.